Learn about the Commissioning, Qualification, and Validation (C&Q) process for regulated industries like pharmaceuticals, biopharma, and biotechnology. In regulated industries, understanding the distinctions between Commissioning,
FDA inspections can be complex, with outcomes ranging from minor observations to formal 483 findings that require prompt and effective response. We often see organizations
FDA inspections rarely focus on a single process or function. We often see inspection outcomes driven by how well quality systems connect across teams, how
Many life sciences organizations approach inspections as episodic events rather than an ongoing discipline. We often see that teams scramble to address findings or prepare
Inspection outcomes often hinge less on isolated deviations and more on how well organizations manage data integrity, documentation, and team competency. We frequently see that
Life sciences organizations are under sustained pressure to advance development programs, expand into global markets, and meet evolving regulatory expectations. We often work with companies
Life sciences organizations today face growing pressure to launch new programs, expand into global markets, and comply with increasingly stringent regulatory requirements. We often see teams needing more
Life sciences organizations are under sustained pressure to advance development programs, expand into global markets, and meet evolving regulatory expectations. We often work with companies